CD22 and acute lymphoblastic leukemia: Spiegel and colleagues reported that bispecific tandem CAR targeting CD19 and/or CD22 in a phase I trial was associated with a 100% response in 17 adult patients with B-ALL including 88% MRD-negative complete remission (CR) 10−4 bone marrow sensitivity.